Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Olinciguat PK in Healthy Volunteers
NCT03892499Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olinciguat in sickle cell disease (SCD), sponsored by Cyclerion Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration of olinciguat and Area under the plasma concentration time curve from time zero extrapolated to infinity. Started May 2019; status: completed.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03892499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892499.